News Category
A new study reveals that specific bacterial strains in a person's microbiome influence the risk of developing sepsis, meningitis, or pneumonia from ai...
Experts emphasize that asking about clinical trials at the first appointment for small cell lung cancer can unlock promising new treatments and improv...
GeoVax has entered a Memorandum of Agreement with CEPI to utilize the CEPI Centralised Laboratory Network for independent testing of clinical samples ...
Tevard Biosciences and collaborators published preclinical research demonstrating that engineered suppressor tRNAs can restore full-length dystrophin ...
Creative Biolabs has broadened its lipid-based delivery capabilities to help researchers engineer carriers that address stability, targeting, and cont...
BioCorRx Inc. appointed Richard J. Baum, former Acting Director of the White House Office of National Drug Control Policy, to its Strategic Advisory B...
Regentis Biomaterials reported first half 2026 financial results, highlighted progress in its pivotal Phase III trial for GelrinC, and received Europe...
Quantum BioPharma's Lucid-MS, a first-in-class drug that protects and rebuilds myelin, has received FDA clearance for a Phase 2 trial that could trans...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, addressing a significant unmet n...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer strengthens its leadership as it advances its BiTAC® T-cell engager an...
Quantum BioPharma receives FDA clearance for a phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug designed to shield and rebuild myel...
Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, is moving into a Phase 2 trial for multiple sclerosis following FDA clearance of its IN...
Quantum BioPharma has received FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug designed to protect and r...
Helus Pharma's CEO will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, potentially boosting the compan...
Onco-Innovations' CMO discussed ONC010, a novel PNKP inhibitor with dual selectivity mechanisms, and its planned first-in-human trial, underscoring th...
Quantum BioPharma's Lucid-MS has received FDA clearance to begin a Phase 2 trial in multiple sclerosis, marking a key step for a first-in-class therap...
Recurrent urinary tract infections (UTIs) are a growing concern for women, yet diagnostic methods remain outdated, leading to prolonged suffering and ...
Silo Pharma's participation in the IPAC-RS forum underscores its commitment to advancing SPC-15, a nose-to-brain drug delivery system for PTSD, with p...
Quantum BioPharma's FDA clearance for a Phase 2 trial of its novel myelin repair candidate Lucid-MS marks a significant milestone that could shift the...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis candidate, has earned a new buy rating and high...
GeoVax applauds the new global mpox vaccine stockpile initiative, highlighting its GEO-MVA candidate as a potential additional source to ensure sustai...
VERAXA Biotech's appointment of Raju Willener as CFO signals its commitment to advancing its BiTAC platform and oncology pipeline with seasoned financ...
Scinai Immunotherapeutics refocuses its R&D portfolio on its NanoAb platform and CDMO business after terminating its PinCell agreement, aiming to opti...
Onco-Innovations advances its oncology pipeline toward clinical trials by securing manufacturing readiness, IND-enabling progress, and funding, positi...
Researchers at Washington University School of Medicine have advanced laser interstitial thermal therapy (LITT) as a promising alternative to open sur...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class drug targeting myelin repair, signals a potential breakthrough in ...
Ocumetics Technology Corp. has initiated patient recruitment for the second phase of its human clinical trial, moving beyond safety to evaluate the pe...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS, a first-in-class myelin repair candidate, marks a pivotal step toward addressing th...
NanoViricides has registered its Phase II trial for NV-387 Oral Gummies against Ebola in the Pan African Clinical Trials Registry, marking a critical ...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial highlights a novel approach targeting demyelination, offering new hope for MS patients an...
Quantum BioPharma's FDA clearance to begin Phase 2 testing of Lucid-MS marks a critical step toward a first-in-class multiple sclerosis therapy that t...
Quantum BioPharma's FDA clearance to advance Lucid-MS into Phase 2 trials for multiple sclerosis marks a significant step toward a novel therapy targe...
Tonix Pharmaceuticals promotes Thomas Englese to CCO to lead commercialization of TONMYA, its first new fibromyalgia treatment in 15 years, signaling ...
A large study reveals that the timing of brain metastasis development significantly impacts survival in colorectal cancer patients, highlighting the n...
Onco-Innovations reports significant progress on its PNKP inhibitor ONC010, including high-purity API production and a novel catalyst, positioning it ...
OS Therapies' participation in the Moody Capital Conference comes as the company anticipates critical regulatory decisions and data releases for its l...
A Swiss preclinical study reveals that administering immunotherapy before surgery significantly improves outcomes for glioblastoma patients, a finding...
The FDA's failure to aggressively enforce regulations has enabled a dangerous black market for the unapproved weight-loss drug retatrutide, putting co...
New research from Mass General Brigham reveals that unintended radiation to the thymus during lung cancer treatment is associated with poorer clinical...
Tonix Pharmaceuticals' participation in the Cantor conference highlights its strategic focus on advancing its CNS and immunology pipeline, including t...
NurExone Biologic will showcase its exosome-based therapeutic platform and U.S. manufacturing plans at the Moody Capital Solutions conference, highlig...
CNS Pharmaceuticals' business development strategy, focusing on in-licensing and acquisitions in oncology and neurology, was highlighted in a Virtual ...
Salman Fazal, MD, a hematologist and transplant specialist at UPMC Hillman Cancer Center, has been named a 2026 Castle Connolly Top Doctor for the thi...
Quantum BioPharma's Lucid-MS, a potential first-in-class treatment for progressive multiple sclerosis, has garnered a 'Buy' rating from Rodman & Rensh...
NanoViricides is progressing its measles drug NV-387 to Phase II trials, leveraging FDA designations and strong preclinical data, which could address ...
TransCode Therapeutics' lead candidate TTX-MC138 shows significant survival benefits in a preclinical breast cancer bone metastasis model, supporting ...
Oragenics reports progress in its Phase IIa trial for a concussion treatment while navigating regulatory feedback and a NYSE American compliance plan.
A nurse's personal battle with metastatic triple-negative breast cancer underscores the importance of new antibody-drug conjugates as first-line treat...
